Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
98.38M
Market cap98.38M
Price-Earnings ratio
-3.32
Price-Earnings ratio-3.32
Dividend yield
Dividend yield
Average volume
2.04M
Average volume2.04M
High today
$0.86
High today$0.86
Low today
$0.8251
Low today$0.8251
Open price
$0.83
Open price$0.83
Volume
673.23K
Volume673.23K
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.3258
52 Week low$0.3258

Stock Snapshot

The current Oncolytics Biotech(ONCY) stock price is $0.83, with a market capitalization of 98.38M. The stock trades at a price-to-earnings (P/E) ratio of -3.32.

On 2026-06-08, Oncolytics Biotech(ONCY) stock traded between a low of $0.83 and a high of $0.86. Shares are currently priced at $0.83, which is +0.4% above the low and -3.7% below the high.

Oncolytics Biotech(ONCY) shares are trading with a volume of 673.23K, against a daily average of 2.04M.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.33 at its lowest and $1.51 at its peak.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.33 at its lowest and $1.51 at its peak.

ONCY News

Investing.com 4d
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com

...

Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Simply Wall St 5d
Why Oncolytics Biotech Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data

In late May and early June 2026, Oncolytics Biotech reported new preclinical and translational data showing pelareorep’s enhanced anti-tumor activity and multi-...

Why Oncolytics Biotech Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data
TipRanks 6d
Oncolytics promotes John McAdory to COO

Oncolytics (ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to COO. Additionally, McAdory has been p...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

More ONCY News

TipRanks 6d
Oncolytics Biotech Strengthens Leadership with New COO, Director

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.